Eye Infections
MOXEZA® Ophthalmic Solution
MOXEZA® (moxifloxacin HCI ophthalmic solution) 0.5% as base, is an antibiotic eye drop used to treat the most common eye infection, bacterial conjunctivitis.
MOXEZA® Solution is dosed two times per day for seven days and is indicated for patients four months of age and older.
Do not wear contact lenses while using MOXEZA® Solution. Patients should not touch the dropper tip to any surface to avoid contaminating the contents.
MOXEZA® Solution should not be injected into the eye. Patients should discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction. The most common side effects of MOXEZA® Solution are eye irritation, fever, and conjunctivitis. Use of MOXEZA® Solution for a long time may lead to other infections.
For U.S prescribing information see the below product insert.
U.S. Product Insert
MOXEZA® Ophthalmic Solution [PDF]
Licensed to Alcon by Bayer Schering Pharma AG.
VIGAMOX® Ophthalmic Solution
VIGAMOX® (moxifloxacin HCI ophthalmic solution) 0.5% as base, is an antibiotic eye drop used to treat the most common eye infection, bacterial conjunctivitis.
VIGAMOX® Solution is dosed three times per day for seven days and is indicated for patients one year and older.
Do not wear contact lenses while using VIGAMOX® solution. Patients should not touch the bottle tip to any surface to avoid the risk of contamination.
This product should not be taken by patients with a sensitivity or allergy to its ingredients. Safety and efficacy have not been determined in children under age 1. Caution should be used when administering this drug to pregnant or nursing women. The most common side effect of VIGAMOX® solution is decreased visual acuity, but patients may also experience burning or stinging, red or itchy eyes, or rash, as well as other effects. If you experience any of these symptoms contact your doctor. For full U.S. prescribing information, see the product insert below.
U.S. Product Insert
VIGAMOX® Ophthalmic Solution [PDF]
Licensed to Alcon by Bayer Schering Pharma AG.
